Nocion Therapeutics Raises $62M in Series B Financing Round to Advance Pain-Relieving Therapies
Clinical-stage biopharmaceutical company, Nocion Therapeutics, has secured $62 million in a Series B financing round, bringing the total funds raised by the company to $122 million. The funding round was led by Arkin Bio Capital and Monograph Capital, with participation from prominent new and existing investors, including Canaan Partners, F-Prime Capital, Mass General Brigham Ventures, Mission BioCapital, and Osage University Partners. As a result of the financing round, Pini Orbach, Ph.D., from Arkin Bio Capital, and Freddie Dear from Monograph Capital, will join Nocion’s Board of Directors.
Nocion Therapeutics, spearheaded by CEO Dr. Richard Batycky, focuses on the development of innovative small molecule compounds called “nocions.” These compounds are specifically designed to target nociceptors, which play a crucial role in the transmission of pain, itch, and cough-related signals. By targeting these actively firing nociceptors, Nocion Therapeutics aims to alleviate the suffering experienced by patients with these conditions.
The company plans to utilize the newly secured funds to propel the development of their lead program, taplucanium dry powder for inhalation, into a Phase 2b study targeting chronic cough patients. This program holds the promise of providing effective relief to individuals plagued by this debilitating condition.
Nocion Therapeutics was established in collaboration with Harvard’s Office of Technology Development and is based on an exclusive license to foundational intellectual property derived from Harvard University and Boston Children’s Hospital. With this strong foundation, Nocion Therapeutics is well-positioned to make significant strides in the field of pain management and improve the lives of countless individuals suffering from these distressing symptoms.
This recent funding round not only showcases the growing interest and confidence in Nocion Therapeutics’ novel therapies but also highlights the company’s commitment to advancing the field of pain therapeutics. The inclusion of experienced industry leaders on the Board of Directors further solidifies Nocion Therapeutics’ position as a frontrunner in this space. As the company forges ahead with its groundbreaking research, many are eagerly awaiting the positive impact that their innovative treatments may have on patients’ lives.
Analyst comment
Positive news: Nocion Therapeutics Raises $62M in Series B Financing Round to Advance Pain-Relieving Therapies.
As an analyst, the market is likely to respond positively to this news. The additional funding will enable Nocion Therapeutics to further develop their lead program, taplucanium dry powder, and advance their innovative pain-relieving therapies. The presence of experienced industry leaders on the board also enhances the company’s credibility. Expectations are high for the positive impact their treatments may have on patients, potentially driving future market growth.
